Texas A&M leads nationwide test of drug to fight COVID-19
Texas A&M University researchers are asking hundreds of frontline medical workers to participate in a late-stage, phase 4, clinical trial of a widely used tuberculosis vaccine that could blunt the devastating effects of COVID-19.
A world-class group of institutions led by Texas A&M is seeking to repurpose the vaccine, BCG, which also is used to treat bladder cancer in the U.S. BCG could be widely available for use against COVID-19 in just six months because it has already been proven safe for other uses.
The Texas A&M University Health Science Center (Texas A&M Health) is leading a group of scientists and medical doctors with Harvard’s School of Public Health, the University of Texas MD Anderson Cancer Center in Houston, Cedars Sinai Medical Center in Los Angeles, and the Baylor College of Medicine in Houston.
Researchers hope to demonstrate that the BCG mitigates the effects of the coronavirus, SARS-CoV-2, allowing fewer people to be hospitalized or to die from COVID-19.
“It’s not going to prevent people from getting infected,” said Jeffrey D. Cirillo, PhD, a Regents Professor in the Department of Microbial Pathogenesis and Immunology at the Texas A&M College of Medicine. “This vaccine has the very broad ability to strengthen your immune response. We call it ‘trained immunity.’
“This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19.”
Texas A&M Chancellor John Sharp last week offered $2.5 million to make sure the work of Cirillo can move forward as quickly as possible.
“If there was ever a time to invest in medical research, it is now,” Chancellor Sharp said. “Dr. Cirillo has a head start on a possible coronavirus treatment, and I want to make sure he has what he needs to protect the world from more of the horrible effects of this pandemic.”
Cirillo said repurposing the existing bladder cancer vaccine, called TICE® BCG, could result in bringing a COVID-19 treatment to the U.S. public in the fastest possible way. Because the drug is already approved by the FDA, Cirillo can skip the first three phases of clinical trials usually required before testing on people, since this vaccine has already passed those phases.
“Before Chancellor Sharp’s investment in our work, we were spending far too much time writing grants. Now, we can move ahead without barriers,” Cirillo said.
Texas A&M is the first U.S. institution in the clinical trial to have federal clearance for testing on humans. Health care workers will be the first people eligible for clinical trial, which is set to begin this week.
Recruitment of 1,800 volunteers to participate in the trial is already underway in College Station and Houston, and it could be expanded to other areas of the state as well as Los Angeles and Boston. Medical professionals interested in the trial can contact Gabriel Neal, MD, at firstname.lastname@example.org or Jeffrey Cirillo, PhD, at email@example.com or George Udeani, PharmD DSc, at firstname.lastname@example.org.
As the coronavirus spread, researchers noticed that the morbidity and mortality rates were lower in some developing countries where the BCG vaccine is widely used.
Because the human body fights a COVID-19 infection in a manner that is similar to how it would attack bladder cancer, Cirillo is hopeful that his work could lead to an effective—and quickly developed—treatment for COVID-19.
Additionally, evidence shows that the coronavirus can cause damage to a patient’s central nervous system, and it even might cause long-term effects that could lead to dementia, Alzheimer’s or Parkinson ’s disease. Cirillo said the potential for lasting effects from COVID-19 is another reason to get the vaccine to the public as quickly as possible.
This article originally appeared in Texas A&M University System News.